Alnylam Pharmaceuticals, Inc. $ALNY Stock Holdings Trimmed by Regeneron Pharmaceuticals Inc.

Regeneron Pharmaceuticals Inc. lowered its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 68.7% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,392,303 shares of the biopharmaceutical company’s stock after selling 3,052,142 shares during the period. Alnylam Pharmaceuticals comprises about 90.6% of Regeneron Pharmaceuticals Inc.’s holdings, making the stock its largest holding. Regeneron Pharmaceuticals Inc.’s holdings in Alnylam Pharmaceuticals were worth $634,890,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. OFI Invest Asset Management raised its holdings in shares of Alnylam Pharmaceuticals by 5.8% during the 3rd quarter. OFI Invest Asset Management now owns 403 shares of the biopharmaceutical company’s stock valued at $184,000 after buying an additional 22 shares in the last quarter. Howard Capital Management Inc. grew its position in Alnylam Pharmaceuticals by 2.9% during the third quarter. Howard Capital Management Inc. now owns 854 shares of the biopharmaceutical company’s stock valued at $389,000 after acquiring an additional 24 shares during the last quarter. Frank Rimerman Advisors LLC grew its position in Alnylam Pharmaceuticals by 2.0% during the third quarter. Frank Rimerman Advisors LLC now owns 1,251 shares of the biopharmaceutical company’s stock valued at $570,000 after acquiring an additional 24 shares during the last quarter. Coastal Bridge Advisors LLC raised its stake in shares of Alnylam Pharmaceuticals by 2.3% during the third quarter. Coastal Bridge Advisors LLC now owns 1,097 shares of the biopharmaceutical company’s stock worth $500,000 after acquiring an additional 25 shares in the last quarter. Finally, Meridian Financial Advisors LLC lifted its holdings in shares of Alnylam Pharmaceuticals by 3.5% in the 3rd quarter. Meridian Financial Advisors LLC now owns 828 shares of the biopharmaceutical company’s stock worth $378,000 after acquiring an additional 28 shares during the last quarter. 92.97% of the stock is currently owned by hedge funds and other institutional investors.

Trending Headlines about Alnylam Pharmaceuticals

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: Canaccord Genuity raised its price target on ALNY to $429 and maintained a “buy” rating, signaling meaningful upside from current levels and helping lift investor sentiment. Read More.
• Positive Sentiment: HC Wainwright reaffirmed a “buy” and set a $510 price target, a notably higher bull case that reinforces optimistic analyst views on Alnylam’s growth prospects. Read More.
• Positive Sentiment: Freedom Capital Markets issued an upgrade on ALNY, which added to the positive analyst chorus and likely contributed to upticks in trading interest. Read More.
• Neutral Sentiment: Several analyst notes trimmed near‑term targets or updated models but generally kept confidence in 2026 growth — a mixed signal that tempers both the bullish and bearish narratives. Read More.
• Neutral Sentiment: Independent valuation pieces describe a mixed picture: bullish fair‑value models versus share-price returns, suggesting some analysts still see long-term upside but valuation expectations vary. Read More.
• Neutral Sentiment: Reported short‑interest figures in the feeds show zero/NaN values and a 0.0 days‑to‑cover — likely a data/reporting artifact rather than actionable new short pressure; treat this as non‑conclusive until exchange data confirms.
• Negative Sentiment: Significant insider selling announced this week: CEO Yvonne Greenstreet sold 6,958 shares (~$310 avg) and several EVPs (including Kevin Fitzgerald, Jeffrey Poulton, Tolga Tanguler, Pushkal Garg) sold multiple blocks at ~$310–332, each trimming mid‑single‑digit percentages of their holdings. Large, clustered insider sales can weigh on near‑term sentiment even if executed for diversification or tax reasons. Read More.

Analyst Ratings Changes

Several equities analysts recently commented on ALNY shares. Leerink Partners reduced their target price on shares of Alnylam Pharmaceuticals from $370.00 to $351.00 and set a “market perform” rating on the stock in a report on Monday, December 15th. Needham & Company LLC cut their price target on shares of Alnylam Pharmaceuticals from $529.00 to $510.00 and set a “buy” rating for the company in a research report on Thursday, February 12th. Wall Street Zen downgraded Alnylam Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday, February 14th. Stifel Nicolaus boosted their target price on Alnylam Pharmaceuticals from $495.00 to $508.00 and gave the company a “buy” rating in a research note on Thursday, December 11th. Finally, Chardan Capital reduced their price target on Alnylam Pharmaceuticals from $475.00 to $425.00 and set a “buy” rating on the stock in a research report on Friday, February 13th. One research analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and five have issued a Hold rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $477.96.

Insider Buying and Selling

In related news, CEO Yvonne Greenstreet sold 9,577 shares of the company’s stock in a transaction on Monday, January 12th. The stock was sold at an average price of $362.86, for a total value of $3,475,110.22. Following the sale, the chief executive officer directly owned 78,411 shares of the company’s stock, valued at $28,452,215.46. This represents a 10.88% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Tolga Tanguler sold 1,959 shares of the company’s stock in a transaction dated Friday, February 13th. The stock was sold at an average price of $310.08, for a total transaction of $607,446.72. Following the completion of the sale, the executive vice president directly owned 31,769 shares in the company, valued at $9,850,931.52. This represents a 5.81% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 36,578 shares of company stock valued at $12,416,105 over the last quarter. 1.50% of the stock is currently owned by insiders.

Alnylam Pharmaceuticals Stock Performance

Shares of ALNY stock opened at $332.68 on Thursday. The firm has a market capitalization of $44.12 billion, a price-to-earnings ratio of 194.55 and a beta of 0.35. The stock has a fifty day moving average of $369.58 and a 200 day moving average of $423.61. Alnylam Pharmaceuticals, Inc. has a 52 week low of $205.87 and a 52 week high of $495.55. The company has a quick ratio of 2.71, a current ratio of 2.76 and a debt-to-equity ratio of 1.28.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings data on Thursday, February 12th. The biopharmaceutical company reported $0.82 EPS for the quarter, missing the consensus estimate of $1.43 by ($0.61). Alnylam Pharmaceuticals had a return on equity of 69.02% and a net margin of 6.43%.The company had revenue of $1.10 billion during the quarter, compared to the consensus estimate of $1.16 billion. During the same quarter last year, the company posted ($0.65) earnings per share. The firm’s revenue for the quarter was up 84.9% compared to the same quarter last year. As a group, research analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.